Brief: Prestige Biopharma And Intas Pharmaceuticals Announce Partnership To Commercialize Bevacizumab Biosimilar
26/07/2022 11:05
July 26 (Reuters) - Prestige Biopharma Ltd 950210.KS :
* PRESTIGE BIOPHARMA AND INTAS PHARMACEUTICALS ANNOUNCE
PARTNERSHIP TO COMMERCIALIZE BEVACIZUMAB BIOSIMILAR IN THE US,
EUROPE, CANADA, MENA, BRAZIL, MEXICO, SOUTH AFRICA, CIS AND THE
SEA COUNTRIES
Source text for Eikon: ID:nBwJhyd0a
Further company coverage: 950210.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prestige Biopharma
See all newsBrief: Prestige Biopharma Wins 2 Billion Won Order
Brief: Prestige Biopharma Receives Final Market Approval From The European Commission For Drug ‘Tuznue,’ For The Treatment Of Breast Cancer And Metastatic Gastric Cancer
Australia's Imagion Biosystems rises on MOU for cancer detection device
Brief: Prestige Biopharma And Intas Pharmaceuticals Announce Partnership To Commercialize Bevacizumab Biosimilar
Brief: Prestige Biopharma Signs Pharmaceutical Contract Manufacturing Agreement With Benevira Inc